Ovid Therapeutics Inc Stock Price, News & Analysis

Ovid Therapeutics (NASDAQ: OVID) appointed Dr. Petra Kaufmann as Chief Medical Officer effective December 2, 2025. Dr. Kaufmann will lead clinical, medical, and regulatory strategy as Ovid advances its clinical pipeline, including next-generation GABA-AT inhibitor OV329 and a portfolio of first-in-class KCC2 direct activators.

She brings experience across industry and government, including leadership roles at Vigil Neuroscience, Affinia Therapeutics, Novartis Gene Therapies and the NIH, and played a key role in development and global approvals of Zolgensma. Her background emphasizes patient-focused trial design, biomarkers, and quantitative clinical planning.

Ovid Therapeutics (NASDAQ: OVID) announced a CEO succession: Meg Alexander will become CEO effective Jan 1, 2026, with Dr. Jeremy Levin transitioning to Executive Chair. The company reported positive Phase 1 biomarker results for OV329 showing strong GABA-AT inhibition and no treatment-related ocular safety findings, and plans a Phase 2a start in Q2 2026. First-in-human data for the IV KCC2 activator OV350 is expected in Q4 2025, and the oral KCC2 activator OV4071 IND is planned for Q1 2026 with a Phase 1/1b start in Q2 2026. Financially, cash and equivalents were $25.6M as of Sept 30, 2025, augmented by an $81M initial private placement, and the company expects funding into 2H 2028. Q3 2025 results: R&D $5.9M, G&A $6.8M, total operating expenses $12.7M, net loss $12.2M ($0.17 per share).

Ovid Therapeutics (NASDAQ: OVID) announced a private placement (PIPE) expected to raise up to $175 million in gross proceeds, including initial gross proceeds of approximately $81 million, before fees and expenses. The PIPE is expected to close on or about October 6, 2025, subject to customary conditions and stockholder approvals.

The financing sells 57,722 shares of Series B preferred, Series A warrants to purchase 38,481,325 common shares and Series B warrants to purchase 28,861,000 common shares. If all preferred conversions and warrants are exercised for cash, Ovid would receive aggregate additional proceeds and issue a total of 125,064,325 common shares. The Company expects existing cash plus initial PIPE proceeds to fund operations into 2028.

Ovid (NASDAQ: OVID) announced positive topline Phase 1 results for OV329 on Oct 3, 2025. In 68 healthy volunteers (51 active; 17 placebo) OV329 5 mg produced robust biomarker evidence of GABA-AT inhibition: LICI inhibition +53% (p=0.0001) on APB and CSP prolongation +12.9 ms (FDI; p=0.00012). MRS showed mean GABA +7.13% in the medial parietal lobe at 5 mg (n=14). Safety was favorable: all treatment-related AEs were mild/transient and no ophthalmic/retinal changes observed through Day 30. Ovid plans a randomized Phase 2a in drug-resistant focal onset seizures in Q2 2026 and will complete enabling work for oral KCC2 activator OV4071 in early 2026.

Ovid Therapeutics (NASDAQ:OVID) reported Q2 2025 financial results and provided key pipeline updates. The company ended Q2 with $38.3 million in cash, expected to fund operations into early 2H 2026. Key highlights include the anticipated Q3 2025 topline readout for OV329 Phase 1 trial, a next-generation GABA-AT inhibitor for treatment-resistant seizures, and a $7.0 million royalty monetization deal with Immedica Pharma AB for ganaxolone rights.

The company is advancing its KCC2 activator portfolio, with OV350's safety data expected in Q4 2025 and OV4071, the first oral KCC2 activator, progressing toward first-in-human studies in Q2 2026. Q2 financial results showed revenues of $6.3 million and a net loss of $4.7 million ($0.06 per share), with reduced operating expenses of $11.3 million compared to $20.7 million in Q2 2024.

Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company focused on developing small molecule medicines for brain conditions, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The conference is scheduled for July 29-30, 2025.

Ovid Therapeutics (NASDAQ:OVID) has entered into a definitive agreement with Immedica Pharma AB to sell its future ganaxolone royalty rights outside China for $7 million in cash. The deal includes the transfer of royalty rights from Ovid's 2022 agreement with Marinus Pharmaceuticals for ganaxolone use in CDKL5 deficiency disorder (CDD). Immedica will also acquire or license Ovid's global ganaxolone intellectual property portfolio and assume related costs.

The transaction provides non-dilutive funding to extend Ovid's operational runway. For reference, Ovid recorded $566,000 in ganaxolone royalty revenues in 2024. The deal has no impact on Ovid's current pipeline as the company has not been pursuing ganaxolone development.

Ovid Therapeutics (NASDAQ: OVID) will host an investor and media event on June 12, 2025, focusing on biomarkers in epilepsy and their OV329 clinical development program. The event will feature Dr. Alexander Rotenberg, a leading pediatric neurologist from Boston Children's Hospital and Harvard Medical School. The presentation will highlight how advanced imaging and radiological tools are being used to identify biological target engagement in drug development. OV329, Ovid's next-generation GABA-aminotransferase inhibitor, is designed to address treatment-resistant seizures, with topline results expected in Q3 2025. The drug aims to provide optimal GABA levels with better safety and tolerability compared to vigabatrin. Currently, about 40% of epilepsy patients continue experiencing seizures despite available treatments. The event will be held at Ovid's New York headquarters and simultaneously webcast.

Ovid Therapeutics (NASDAQ: OVID) reported Q1 2025 financial results and pipeline updates. The company's lead program OV329, a GABA-AT inhibitor for drug-resistant epilepsies, is progressing with topline results expected in Q3 2025. Their OV350 program, the first-ever KCC2 direct activator, began Phase 1 trials in Q1 2025. The company reported $43.0 million in cash and equivalents, expected to fund operations into 2H 2026. Q1 financial results showed revenues of $130,000, R&D expenses of $6.7 million (down from $10.4M), and a net loss of $10.2 million ($0.14 per share). The company's pipeline includes multiple promising candidates, with their oral KCC2 activator OV4071 planned for clinical development by year-end, targeting psychosis in neuronal-synuclein diseases.